Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:GOSS NASDAQ:IVA NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.74-1.9%$6.01$3.93▼$7.32$299.27M1.51701,305 shs774,254 shsGOSSGossamer Bio$1.36$1.22$0.66▼$1.55$309.13M1.861.44 million shs696,002 shsIVAInventiva$3.35-0.9%$3.32$1.53▼$4.05$323.34M0.7364,542 shs20,641 shsQNCXQuince Therapeutics$1.82+2.2%$1.25$0.51▼$2.45$80.93M0.96312,838 shs492,644 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-1.88%-2.78%-7.72%+24.78%+15.03%GOSSGossamer Bio0.00%+11.02%+5.43%+64.85%+16.24%IVAInventiva+1.36%+9.48%-5.37%-0.30%+31.89%QNCXQuince Therapeutics+2.25%+13.40%+45.60%+82.00%+152.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.7639 of 5 stars3.51.00.04.51.82.50.0GOSSGossamer Bio3.8262 of 5 stars3.51.00.04.72.71.70.0IVAInventiva3.1914 of 5 stars3.45.00.00.02.41.70.6QNCXQuince Therapeutics3.3514 of 5 stars3.64.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$19.25235.37% UpsideGOSSGossamer Bio 3.00Buy$7.33439.22% UpsideIVAInventiva 2.80Moderate Buy$10.40210.45% UpsideQNCXQuince Therapeutics 3.29Buy$8.00339.56% UpsideCurrent Analyst Ratings BreakdownLatest QNCX, ABEO, IVA, and GOSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/4/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/2/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$19.005/16/2025ABEOAbeona TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $20.005/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.005/15/2025ABEOAbeona TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/30/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M83.90N/AN/A$1.01 per share5.68GOSSGossamer Bio$114.70M2.70N/AN/A$0.13 per share10.46IVAInventiva$9.95M32.21N/AN/A($1.21) per share-2.77QNCXQuince TherapeuticsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M-$1.27N/AN/AN/AN/A-118.82%-52.48%8/11/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)QNCXQuince Therapeutics-$56.83M-$1.39N/AN/AN/AN/A-117.52%-34.22%8/12/2025 (Estimated)Latest QNCX, ABEO, IVA, and GOSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ABEOAbeona Therapeutics-$0.35-$0.24+$0.11-$0.24N/AN/A5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/13/2025Q1 2025QNCXQuince Therapeutics-$0.24-$0.34-$0.10-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.274.904.90GOSSGossamer Bio6.705.715.71IVAInventivaN/A0.920.92QNCXQuince Therapeutics0.824.054.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%GOSSGossamer Bio81.23%IVAInventiva19.06%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%GOSSGossamer Bio6.70%IVAInventiva32.00%QNCXQuince Therapeutics20.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.16 million47.63 millionOptionableGOSSGossamer Bio180227.30 million212.07 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableQNCXQuince Therapeutics6045.47 million36.24 millionOptionableQNCX, ABEO, IVA, and GOSS HeadlinesRecent News About These CompaniesQuince Therapeutics Appoints Leading Immunologist Dr. Hassan ...3 hours ago | finance.yahoo.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory BoardJuly 10 at 4:05 PM | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from BrokeragesJune 26, 2025 | marketbeat.comQuince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research ConferenceJune 25, 2025 | businesswire.comQuince Therapeutics Announces Closing of Up to $22 Million Private Placement of SecuritiesJune 18, 2025 | businesswire.comQuince Therapeutics raises $11.5 million in private placementJune 14, 2025 | investing.comQuince Therapeutics Raises $11.5M in Private PlacementJune 13, 2025 | tipranks.comQuince Therapeutics' (QNCX) Buy Rating Reaffirmed at D. Boral CapitalJune 13, 2025 | marketbeat.comQuince Therapeutics Announces Pricing of Up to $22 Million Private Placement of SecuritiesJune 12, 2025 | businesswire.comQuince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJune 3, 2025 | businesswire.comQuince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026May 15, 2025 | seekingalpha.comQuince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finance.yahoo.comQuince Therapeutics to Present at Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comQuince Therapeutics to Present at Jones Healthcare and Technology Innovation ConferenceApril 3, 2025 | businesswire.comAnalysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)March 27, 2025 | markets.businessinsider.comQuince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial ResultsMarch 24, 2025 | businesswire.comOppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform RecommendationMarch 24, 2025 | msn.comQuince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-TelangiectasiaFebruary 7, 2025 | businesswire.comQuince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | businesswire.comQuince Therapeutics gets USPTO notice of allowance in Ataxia-TelangiectasiaFebruary 4, 2025 | markets.businessinsider.comQuince Therapeutics secures USPTO nod for A-T treatment patentFebruary 4, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffWhy SailPoint May Cruise Past Cybersecurity Rivals in 2025By Nathan Reiff | June 18, 2025View Why SailPoint May Cruise Past Cybersecurity Rivals in 2025Lululemon Slips as Rivals Rally: 3 Stocks to WatchBy Dan Schmidt | June 30, 2025View Lululemon Slips as Rivals Rally: 3 Stocks to WatchQNCX, ABEO, IVA, and GOSS Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.74 -0.11 (-1.88%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$5.71 -0.03 (-0.45%) As of 07/11/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Gossamer Bio NASDAQ:GOSS$1.36 0.00 (0.00%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.37 +0.01 (+0.74%) As of 07/11/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Inventiva NASDAQ:IVA$3.35 -0.03 (-0.89%) Closing price 07/11/2025 03:55 PM EasternExtended Trading$3.36 +0.01 (+0.27%) As of 07/11/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Quince Therapeutics NASDAQ:QNCX$1.82 +0.04 (+2.25%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.88 +0.06 (+3.30%) As of 07/11/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
